Caxton Associates (New York)’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-20,762
| Closed | -$413K | – | 522 |
|
|
2024
Q3 | $413K | Buy |
+20,762
| New | +$413K | 0.02% | 388 |
|
|
2022
Q3 | – | Sell |
-32,338
| Closed | -$227K | – | 490 |
|
|
2022
Q2 | $227K | Sell |
32,338
-92,264
| -74% | -$648K | 0.02% | 431 |
|
|
2022
Q1 | $1.03M | Buy |
124,602
+83,992
| +207% | +$696K | 0.08% | 83 |
|
|
2021
Q4 | $275K | Hold |
40,610
| – | – | 0.03% | 407 |
|
|
2021
Q3 | $215K | Sell |
40,610
-2,413
| -6% | -$12.8K | 0.02% | 363 |
|
|
2021
Q2 | $247K | Buy |
43,023
+18,431
| +75% | +$106K | 0.03% | 343 |
|
|
2021
Q1 | $113K | Hold |
24,592
| – | – | 0.01% | 373 |
|
|
2020
Q4 | $82K | Buy |
24,592
+13,039
| +113% | +$43.5K | 0.01% | 113 |
|
|
2020
Q3 | $34K | Sell |
11,553
-94,149
| -89% | -$277K | ﹤0.01% | 279 |
|
|
2020
Q2 | $488K | Buy |
105,702
+79,622
| +305% | +$368K | 0.04% | 130 |
|
|
2020
Q1 | $100K | Buy |
+26,080
| New | +$100K | 0.02% | 380 |
|